Form 4 Filing for Anika Therapeutics, Inc.

John B. Henneman III, a director at Anika Therapeutics, Inc., acquired 5,000 shares of common stock on May 1, 2026. The weighted average price for these shares was $14.6639, with individual purchases ranging from $14.595 to $14.75. Following this transaction, Mr. Henneman III now directly owns 54,871 shares of Anika Therapeutics, Inc. common stock. This filing is made on Form 4, indicating a change in beneficial ownership.